Akeso's ivonescimab faces high‑stakes scrutiny at ASCO 2026 plenary with HARMONi‑6 overall survival readout in lung cancer

Akeso's bispecific antibody ivonescimab (AK112) is scheduled for a high‑profile plenary late‑breaking presentation at the ASCO 2026 Annual Meeting on May 31, 2026, in Chicago, spotlighting the overall survival (OS) results from the phase 3 HARMONi‑6 trial in advanced squamous non‑small cell lung cancer (sq‑NSCLC). The trial compares ivonescimab plus chemotherapy against tislelizumab plus chemotherapy in previously untreated patients, with the OS data constituting the pivotal readout after prior positive progression‑free survival (PFS) results. Medical and financial observers are closely watching whether the survival benefit translates into a statistically significant OS advantage, since earlier Harmoni‑series data were mixed; share prices in Summit Therapeutics, Akeso’s partner, already fell sharply in 2025 when a prior Harmoni OS analysis missed statistical significance. The plenary slot (LBA4, 2:47–2:59 p.m. CDT, presenter:
Prof. Shun Lu, Shanghai Chest Hospital) underlines both the drug’s strategic importance and the pressure on Akeso/Summit to demonstrate robust, durable survival gains in a highly competitive first‑line lung‑cancer market.